Introduction
Recent progress in human genetics, especially in human genome research and gene transfer techniques, has brought gene therapy closer to clinical reality. Experimental human gene therapy has enjoyed some successes in the treatment of genetic defects, including adenosine deaminase deficiency, [1] [2] [3] familial hypercholesterolemia, 4 hemophilia 5 and cystic fibrosis, 6 and acquired diseases such as cancer, 7 heart disease, 8 kidney disease 9 and acquired immunodeficiency syndrome. 10 At present, the primary limitation in the use of gene therapy to treat human disease is the ineffectiveness of gene delivery methods. Among several types of gene delivery systems for human gene therapy in clinical trials, the Moloney murine leukemia virus (MoMLV)-based vectors are the most widely used. [11] [12] [13] [14] MoMLV-based vectors offer highly efficient chromosome integration; thus, the therapeutic genes are transmitted to the progeny cells. However, the MoMLV-based gene delivery method is largely limited to the ex vivo protocol, [1] [2] [3] [4] [5] in which the target cells are removed from the patient to receive therapeutic genes from the MoMLV vectors in vitro. Then the transduced cells are selected, expanded and reimplanted in the patient. The ex vivo procedure is cumbersome and costly, and in most cases, it can transduce only a small fraction of the target cell population. 15, 16 For advancing gene therapy to routine clinical practice, more efficient gene delivery protocols need to be developed.
In vivo gene transfer is conceptually attractive and potentially can be more efficient than the ex vivo procedure. However, due to limited titer 14 and short half-life
Correspondence: X Lin Received 11 November 1997; accepted 30 March 1998 at body temperature, direct administration of retroviral vectors into patients is unlikely to succeed. Another alternative is to introduce producer cells directly into patients. In this scenario, gene transfer may continue in vivo for the duration of the life span of the implanted producer cells. Gene therapy using MoMLV-based producer cells to treat brain tumors 17 has been carried out in clinical trials, but no clear clinical benefit has been reported. Murine producer cells are rapidly inactivated in human serum; 18, 19 thus, the lack of success in this case is not surprising. The implanting of established human producer cell lines, however, risks the introduction of malignancy into the recipient. For these reasons, we previously proposed to convert human primary cells into producer cells. 20 The primary cell-converted 'producer cells' do not have the drawbacks discussed above, yet they have the advantages of in vivo gene delivery.
To be converted to producer cells the primary cells must acquire the therapeutic or marker gene and MoMLV structural genes gag, pol and env. The former can be delivered by a conventional MoMLV-based vector while the latter, as will be described below, can be delivered by adenoviral vectors. These results establish that different existing gene delivery systems can be combined to produce new, and possibly more powerful, gene delivery constructs.
Results
Construction and functional tests of adenoviral vectors Adenoviral vectors are an attractive choice for the transfer of MoMLV gag-pol-env genes into target cells since they have proven gene transfer efficiency and can accommodate a large insert. For this purpose, four different fragments of MoMLV genes have been cloned separately into adenoviral vector p⌬E1Asp1A (p⌬E1A, which is used as prefix for the derived vectors, Figure 1 ) and tested for their functionality. Vector p⌬E1A-N/H, which contains all three MoMLV structural genes, was transfected by calcium phosphate coprecipitation method into 293-␤ cells, which contain an integrated marker ␤-galactosidase gene originally transduced from a retroviral vector. The expression of MoMLV structural genes would rescue the marker gene, and package it into the resulting retroviral vectors. In parallel experiments, the parent vector (p⌬E1A) and the vector containing the insert, pPAM3 21 ( Figure 1 ) were transfected into the same cells as negative and positive controls, respectively. The supernatants of the cells were used to infect NIH TK − cells 22 (NIH 3T3 or 3T3 cells), which were stained with X-gal. The results, presented in Table 1 , clearly showed that when transfected into 293-␤ cells, p⌬E1A-N/H can rescue the ␤-gal gene in a retrovirus vector.
Construction of recombinant adenoviruses based on these vectors was then attempted. The MoMLV insert in vector p⌬E1A-N/B is near the size limit of 8.3 kb for recombination with pBHG11 in 293 cells. 23, 24 Efforts to obtain recombinants using this system were fruitless. Successful recombinant adenovirus derived from p⌬E1A-N/H (7.9 kb, at maximal insert size for rescue into BHG10
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) and pBHG10 was obtained after hundreds of transfection attempts. The resulting recombinant adenovirus vector Ad-N/H-1 has the capacity to deliver all MoMLV gag-pol-env genes. For comparison, we have also obtained recombinants between pBHG10 and either p⌬E1A-gp or p⌬E1A-env. These recombinant vectors separately deliver MoMLV gag-pol genes (Ad-gp2) and env gene (Ad-env3). duction in the supernatants. The results showed that while the supernatants from PA317 clones contain 0.25 ng/ml RT, the supernatants from Ad-N/H-1-and Adgp2-infected cells contain RT from 0.02-8 ng/ml, depending on the dose and duration of the adenovirus infection. These results clearly demonstrate that the transfer of MoMLV genes by the adenoviral vectors resulted in the proper expression of MoMLV proteins for the packaging of MoMLV particles.
Cotransduction of cells with retroviral and adenoviral vectors to generate new producer cells
In order to transduce cloned cells into producer cells, the marker genes neoR (from pLN) and neoR + lacZ (from pLNPOZ) were first transduced into NIH 3T3 and Hela cells, and high-titer clones were selected (see Materials and methods). When different amounts of recombinant adenovirus Ad-N/H-1 were used to infect both mouse fibroblast cell line NIH 3T3-LN clones and human T cell line H9-LN, 27 the resulting titers correlate with the amount of adenoviral vector used at dosages below saturation (Table 2 ). Table 2 also shows that the titers are zero without recombinant retrovirus. These results clearly show that the 'naive cells' were transduced into the second generation producer cells by a combination of retroviral and adenoviral vectors. The titers generated from the new producer cells resulting from different procedures were investigated. Several retroviral vector transduced and cloned cell lines, NIH 3T3-LN, NIH 3T3-LNPOZ and Hela-LN, which contain marker genes, were transduced separately with Ad-N/H-1 or Ad-gp2 + Ad-env3 using high multiplicity of infection (MOI), ranging from 5:1 to 10:1. Table 3 shows that the titers for the 3T3 clones ranged from 3 × 10 4 to 3 × 10 5 c.f.u./ml and for HeLa clones ranged from 8 × 10 3 to 1 × 10 4 c.f.u./ml. Control cells without adenoviral vector infection or with either Ad-gp2 or Ad-env3 alone resulted in zero titer. The sensitivity of HeLa cells to the cytopathic effect of Ad-N/H-1 may account for the titer being lower than that from 3T3 cells. Co-infection of Adgp2 + Ad-env3 resulted in a titer about 10 times lower than that from Ad-N/H-1, possibly because of the uneven transfer and expression of gp2 and env3 genes in individual producer cells. In separate experiments, 3T3, H9 and Hela cells were transduced with retroviral vector LN and selected for neoR. The resulting uncloned cell populations (pools) were infected with Ad-N/H-1 and their titers determined (Table 4) . Values for some of these titers were expectedly lower than those from the cloned cells (Table 3) . This was likely due to the heterogeneous integration and expression of the retroviral vectors.
The integration of retroviral gene into host genome was analyzed by the identification of pLN originated sequence in cellular DNA. Genomic DNA from transduced cells was digested with BamHI, a site absent in LN gene, and size-separated by agarose gel electrophoresis. The location of LN gene was identified by polymerase chain reaction (PCR) using the cut gel slices as templates. DNA from cloned 3T3 cells transduced with pLN (NIHpLN-1) showed a single LN-positive band at 9 kb. As expected, an uncloned pool of NIH-LN showed a broad range of LN-positive bands ranging from 6 to 9 kb (results not shown). No positive band was detected in the untransduced 3T3 cells. These results clearly showed the single-site integration of the NIH-pLN-1 and the heterogenous integration of the NIH-pLN-pool. Attempts were made to convert human peripheral blood mononuclear cells (PBMCs) into producer cells. PBMCs were simultaneously superinfected with both retroviral and adenoviral vectors and then titrated without selection. With this simplified procedure, the titers were predictably lower for all three cells. The titer of PBMCs were about 100-200 c.f.u./ml, which is similar to that produced by NIH 3T3 (320 c.f.u./ml) and HeLa (21 c.f.u./ml) cells. These data suggest that the current vectors have the potential to achieve acceptable titers for the second generation producer cells originating from different cell types. These results also demonstrate that human primary cells can be converted into producer cells by superinfection of retroviral and adenoviral vectors.
The decay of titer in the culture supernatants of the new producer cells was analyzed during continued cell culture. After three splits of cultured cells at 2-day intervals, the titers decreased by about 10-fold (Table 5 ). These results demonstrate that reasonable titers can be maintained over a short duration even though adenovirus transduction does not result in the integration of the MoMLV genes into the host chromosomes. Experiments were designed to test the current vectors under different conditions. The adenoviral vectors carrying MoMLV structural genes were able to rescue two different MoMLV markers (pLN and pLNPOZ) in three different cell lines (NIH 3T3, Hela and H9). The pools of retrovirus-transduced cells were also tested for adenoviral infection. Although this method is expected to produce lower titers it is, nevertheless, a closer simulation for certain clinical applications, in which primary cells are first transduced with retroviral vectors, selected, then infected with adenoviral vectors. Our results showed that the vectors still worked reasonably well even with this rapid procedure. Moreover, co-infection by both retroviral and adenoviral vectors without selection was also shown to work. These results showed that the vectors were reliable even under less than optimal conditions. Finally, since the genes transferred from the adenoviral vectors are not chromosome-integrated, we tested the decline of titers from later cell generations. The data suggested that the decline of titers from the constructed producer cells was reasonably slow over time in further culturing.
The conversion of target cells into retroviral producer cells can, at least in theory, be accomplished by different methods in which the MoMLV structural genes and the marker genes can be transferred separately. The idea was first reported using a combination of MoMLV and HIV-based gene delivery to construct new packaging cells. 20 Noguiez-Hellin et al 28 reported that by engineering MoMLV gagpol and env genes separately into a single plasmid, which is called plasmovirus, they can transform target cells into retroviral packaging cells by plasmid transfection. Recently, Savard et al 29 reported the use of defective herpes simplex virus to deliver MoMLV structural genes, and demonstrated that the recombinant herpes virus can rescue defective retrovirus vectors in a permanent cell line. The use of adenoviruses to deliver both MoMLV structural genes and MoMLV vectors has been reported. 30, 31 These authors also observed the secondary, permanent gene transfer in an in vitro and in vivo model after the primary adenoviral infection. In addition, tetracycline-controllable transactivator has been used to drive the expression of vesicular stomatitis virus G-protein (VSV-G) and MoMLV gag-pol in adenovirus vectors. 32, 33 These adenoviral vectors have been used to rescue retroviral vectors and results in production of high-titer VSV-G-pseudotyped retroviruses in the supernatants. Together with the results described in this paper, these independent studies have firmly established that the new methods of producing retroviral producer cells have good potential for creating an efficient new generation of retroviral gene delivery systems for human gene therapy.
The new producer cells transduced by adenoviral and retroviral vectors from primary cells may ultimately be introduced into patients to deliver therapeutic genes to target cells in vivo. Such a protocol has the advantage of a continuing in vivo gene transfer over the lifetime of the 'producer cell'. This is also a safe procedure because both MoMLV and adenovirus-based gene delivery has been widely used in human gene therapy clinical trials. [1] [2] [3] [4] [5] [34] [35] [36] Also, since long-term survival of the producer cells in a patient is not essential in this method, then, unlike the ex vivo protocol, the producer cells need not necessarily be from the same patient. Thus, there is potential to develop industrial-scale universal therapeutic producer cells to treat many patients with similar defects.
Materials and methods

Adenoviral vector construction
Four adenovirus vectors ( Figure 1) were constructed. Vector p⌬E1A-N/B was obtained by inserting an 8.3-kb NheI-Bst1107 I fragment from pPAM3, 21 which contains the MoMLV left-side LTR, gagpol/env genes without packaging signal, and a polyadenylation signal, into XbaIEcoRV site of vector p⌬E1Asp1A (Microbix Biosystems, Toronto, Canada). Vector p⌬E1A-N/H was constructed by inserting a 7.9-kb NheI-HpaI fragment from pPAM3, which contains MoMLV LTR, and gagpol/env genes without polyA signal, into the EcoRV site of p⌬E1Asp1A. Vector p⌬E1A-gp contains MoMLV gag-pol genes derived from p⌬E1A-N/B in which an EcoRI fragment at the 3Ј-end containing part of the MoMLV env was deleted. Vector p⌬E1A-env was produced as follows: an XbaI site in the left LTR of pPAM3 was eliminated by partial XbaI digestion and Klenow fill-in. The resulting plasmid was digested with PvuI-XbaI, filled-in with Klenow, and the vector was religated. These steps eliminated most of the gag-pol genes. The resulting vector was then cut with NheI-HpaI, and the 4.66 kb fragment, containing MoMLV env, was inserted into EcoRV site of p⌬E1Asp1A.
Transfection of 293-␤ cells 293-␤ Cells (described below) were transfected with pPAM3 and p⌬E1A-N/H by calcium phosphate transfection method 37 using a commercial kit from Promega (Perfection Mammalian Transfection System; Promega, Madison, WI, USA). Cells were grown for 48 h after transfection, and the supernatants were then recovered, filtered through a 0.45 m filter, and used to infect NIH 3T3 cells in six-well culture dishes in the presence of 8 g/ml polybrene. The infected 3T3 cells were trypsinized 24 h later, and transferred to 10-cm cell culture dishes with neomycin selection (0.75 mg/ml active G418; Mediatech, Herndon, VA, USA). Colonies were grown for 7-10 days and were stained with crystal violet (0.1% in 20% ethanol) before being counted.
Transduction of cells with retroviral vectors containing neoR gene
MoMLV-based vectors were either transfected into an intermediate ecotropic packaging cell line GP+E-86 38, 39 using calcium phosphate transfection as described above or lipofectamine transfection (Life Technologies, Gibco-BRL, Gaithersburg, MD, USA) and resultant virus used to infect an amphotrophic packaging cell line PA317, 21 or directly transfected into PA317. The three vectors used were as follows: vector pLN which contains neoR, 40 vector pLNPOZ which contains neoR and lacZ 41 and vector pLNCX-␤. The latter was constructed by inserting a 3.7-kb HindIII-BamHI fragment containing the lacZ gene from pCH110 (Pharmacia Biotech, Piscataway, NJ, USA) into the HindIII site of pLNCX. 40 The resulting producer cells from separate transfection of the three vectors are called PA317-LN, PA317-LNPOZ and PA317-␤, respectively. These producer cells were then colony purified, with resulting titers ranging from 10 5 to 10 7 c.f.u./ml. All of these cell lines were free of replication-competent virus, as determined by marker-rescue assay. 40 Culture supernatants were used to transduce NIH 3T3, Hela, H9 and 293 cells. Neomycin-resistant cells were selected by neomycin analog G418 (0.75 mg/ml active). Cloned cells of 3T3-LN, 3T3-LNPOZ, Hela-LN and 293-␤ were thus obtained (nomenclature: cell name-MoMLV vector). To characterize the marker gene-containing cell lines, between 20 and 30 colonies of each of 3T3-LN, 3T3-LNPOZ and Hela-LN clones were tested. These clones were infected with an equal amount of recombinant adenovirus Ad-N/H-1 to rescue the marker gene, and the supernatants of the culture medium were titrated on 3T3 cells. The resulting titers showed that about 20-30% of the original clones produced high titers in their supernatants after infection with Ad-N/H-1. The high-titer clones were then used for further testing. H9-LN is an uncloned neoR-containing cell pool. All these cells were free of replication-competent virus, as judged by the absence of neoR phenotype in 3T3 cells infected with the culture supernatants.
Recombinant adenovirus construction
To obtain recombinant adenoviruses, each of the four vectors was cotransfected with either pBHG11 or pBHG10 24 into 293 cells by the calcium phosphate method, basically as described. 42, 43 Briefly, 293 cells were split into 60-mm culture dishes the day before transfection in a density that resulted in 70-80% confluency on the day of transfection. Adenovirus vectors were trans-fected into 293 cells by the calcium phosphate method 37 using a commercial kit (Promega) according to the manufacturer's instructions. Six to ten g of each DNA was used for cotransfection. Transfected 293 cells were incubated overnight in a CO 2 incubator and then the culture media were aspirated and replaced with fresh media of 5% horse serum (HS)/MEM. Cells were transferred to 10-cm dishes when confluent, and the cytopathic effect was observable in 1-2 weeks. The resulting recombinant viruses were separately plaque-purified, expanded in 293 cells and then purified in a CsCl gradient.
42, 43 The CsCl gradient-purified adenoviral vectors were used for delivering MoMLV gagpol and env genes. In addition, DNA was extracted and purified from the CsCl-purified viruses and the constructs were verified by restriction digestion and nucleotide sequencing.
Western blot analysis and RT assay Cells were detached from plates with EDTA and dissolved in sample buffer in the presence of ␤-mercaptoethanol at a concentration of 0.1 mg cell weight (wet) per microliter. This resulted in protein concentration of approximately 1 mg/ml. Five microliters of the sample were applied to 10% SDS-polyacrylamide gel (Novex precast gels in Tricine buffer, from Novex, San Diego, CA, USA) and blotted on to PVDF membrane according to standard procedures. The membrane was then probed with pig anti-amphotrophic MoMLV serum (Quality Biotech, Camden, NJ, USA), washed, and then reacted with rabbit anti-pig IgG-peroxidase conjugated (Sigma Chemical, St Louis, MO, USA). The blot was developed with an enhanced chemiluminescent substrate from PIERCE (Rockford, IL, USA) according to the manufacturer's instructions. RT assay was performed using a commercial kit (Boehringer Mannheim, Indianapolis, IN, USA), which is based on a colorimetric enzyme immunoassay method. A buffer system adapted for MoMLV RT assay was used and the amount of RT was calibrated according to HIV RT standard.
Generation of retroviral producer cells by retroviral and adenoviral infection
Hela or 3T3 cells were grown in DMEM/10% FCS and then plated in six-well plates with 2.4 × 10 5 cells per well at day 1 to reach about 40-60% confluence at day 2. All culture media containing the MoMLV virus-like particles were centrifuged at 500 g for 10 min in a Beckman (Palo Alto, CA, USA) GPR centrifuge. To avoid possible contamination from producer cells, only the top layers of the centrifuged supernatant were used for infection. Frozen supernatants were thawed and centrifuged only, while fresh supernatants were centrifuged and then filtered through 0.45 m filters before being used for infection. The cells were separately infected with the supernatants from MoMLV producer cells PA317-LN or PA317-LNPOZ in the presence of 8 g/ml polybrene and adenoviral vectors Ad-N/H-1, Ad-gp2 and Ad-env3. Cells were washed with medium three times after infection to remove residual retroviral particles completely and then cultured for an additional 2 days. Supernatants were then harvested and frozen at −70°C for titer analysis. Titers were determined on 3T3 cells according to standard clonogenic assay 40 procedure with G418 selection. Briefly, 3T3 cells were plated in six-well plates, as described above, the day before infection. After infection with different dilutions of supernatants in the presence of polybrene, the cells were incubated in a CO 2 -incubator for 24 h before being transferred into 10-cm dishes and selected with G418 (0.75 mg/ml active G418). Selection media were changed after each period of 2-3 days, and colonies were stained with either crystal violet (0.1% in 20% ethanol) or X-gal before counting. Marker rescue assays 40 were performed for these supernatants, using 3T3-LN clones as templates and replication-competent virus was found in none of the supernatants tested. Controls include 3T3 and Hela cells infected with supernatants from either PA317-LN or PA317-LNPOZ alone, or infected with adenoviral vectors alone. Additional controls include infection of 3T3-LN, 3T3-LNPOZ and Hela-LN clones with either Ad-gp2 or Ad-env3 alone. All of these controls produced no count when titrated on 3T3 cells.
Genomic analysis of NIH 3T3-pLN cells
Three different cells were used to analyze the genomic integration patterns of retroviral vectors. NIH 3T3 cells were used as negative controls. A clone of NIH-pLN, NIH-pLN-1, was used as single-site integration cells. A population of NIH 3T3 infected with retroviral vector carrying pLN, NIH-pLN-pool, was used as multiple-integration cells. Genomic DNA was purified from cells (3 × 10 6 ) using a commercial kit (Wizard Genomic DNA Purification System, Promega) according to the manufacturer's instructions. The DNA (7 g) from these three cell lines was digested with BamHI, which is not cut in the pLN gene, and then separated on 1% agarose gels. The gels were cut into nine equal sections from 3 to 20 kb, and about 5 l from each section was used as templates for PCR amplifications. Two internal primers of pLN were used for the PCR: forward primer 5Ј-CCCGATTCGCAGCGCATCGCCTTCTATCGC; and reverse primer 5Ј-GCAGAGGAGACCCTCCCAAG. PCR was performed with a 'touch-down' method, with separation for 40 s at 94°C, extension for 60 s at 72°C, and various annealing temperatures of 55°C, 53°C, 50°C for five cycles each followed by 48°C, 46°C, 44°C for 10 cycles each. A 0.67-kb band is expected from the PCR, which showed in some sections of NIH-pLN-1 and NIH-pLNpool, but not in NIH 3T3 DNA.
Isolation and infection of PBMCs
PBMCs were isolated from healthy donors by FicollHypaque density-gradient centrifugation and cultured initially in RPMI 1640 medium containing 20% FCS in the presence of phytohemagglutinin (PHA-P, from Sigma, 5 g/ml). Continuous culture of the cells was done in the same media with interleukin-2 (human recombinant IL-2 from GibcoBRL, 200 U/ml). 44 PBMCs (9 × 10 6 in 5 ml) were infected with 5 ml of supernatant from PA317-LNPOZ (5.8 × 10 6 c.f.u./ml) in the presence of 8 g/ml polybrene for 4 h. Cells were washed three times with PBS, and then resuspended in 6 ml of growth medium with IL-2. Cells were seeded into a 24-well plate with 1 ml aliquots, and infected with Ad-N/H-1 with MOI of 0, 5, 10, 20, 50 and 100. Supernatants from the infections were harvested 2 days later, and titrated on NIH 3T3 cells as described above.
